Hengrui’s innovative-drug engine, global licensing pipeline and net-cash balance support long-term upside despite premium valuation and Chinese pricing pressure.
Overview
Jiangsu Hengrui Pharmaceuticals is mainland China’s premier innovative biopharmaceutical company, transitioning from a generic manufacturer into a proprietary-drug developer spanning oncology, metabolic, cardiovascular, immunology, anesthesiology and pain management. It generated RMB 31.63 billion of FY2025 revenue, including RMB 16.34 billion from innovative drugs and RMB 3.39 billion of licensing income, which rose 25.62%. **The investment case rests on a dual engine of domestic innovative-drug commercialization and global out-licensing royalties.** Q1 2026 revenue rose 12.98% year over year to RMB 8.14 billion, while attributable net profit increased 21.78% to RMB 2.28 billion and operating cash flow rose 41.66% to RMB 786.45 million. R&D spending was RMB 2.22 billion, or 27.32% of quarterly revenue, supporting 26 clinical-trial approvals and eight accepted NDAs. The shares traded at HKD 52.80, below the HKD 57.27 200-day moving average and at 42.98x trailing P/E versus a 27.5x peer average, so execution is already valued at a premium. Nevertheless, the probability-weighted five-year target is HKD 81.27, with catalysts including clinical milestones, NRDL-driven product ramps and the NewCo globalization strategy.